qordata thought leaders and subject matter experts share their insights and experiences
Accidental discovery. Life changing consequence. Happens all the time, doesn’t it? Penicillin wouldn’t have been discovered if Alexander Fleming hadn’t observed unusual growth in his lab equipment. For others in the life sciences industry—particularly in compliance—discoveries don’t always have happy endings. Data discoveries are best made quickly and internally. Yet, that doesn’t seem to happen often enough. In listing “Best Practices For Compliance Analytics,” at the 7th Annual Global Transparency Reporting Congress, Mohammad Ovais, CEO and founder qordata mentioned how this very basic step was overlooked by decision-makers across the pharma compliance/transparency space. For many pharmaceuticals, this happens because their compliance team defers to counterparts in technology. Should they wait for an analytics system to be up in place before […]
“If it ain’t broke, don’t fix it.” Pharmaceutical compliance serves the industry well by doing the exact opposite. In “Using Data Analysis For Business And Compliance Monitoring,” a qordata webinar I co-presented with Alice Cabrio, I described some of the proactive measures that have shifted compliance from functional support to an area of strategic centrality. Introducing Substantial Compliance at Roche Italy is one of them. Traditional Compliance, whose purpose is borne out of extrinsic reporting, is often reactive and diagnostic. Its approach is to meet expectations. Literally, to just comply. In other words, if the data in traditional compliance gives no indication of disease, there’s no need to look further. My team and I have managed to evolve things at […]
Mohammad Ovais, founder/CEO, qordata was one of the keynote speakers at the 7th Annual Global Transparency Reporting Congress in UK. Titled, “Best Practices For Compliance Analytics,” the session provided guidelines for optimizing internal data for Transparency/Compliance in the global pharmaceutical industry.
Can Compliance take the center stage from its traditional role as a supporting actor in corporate machinery? According to Fausto Massimino and Alice Cabrio, both from Roche Italy, the answer is yes. Compliance can provide business centers with the tools needed for better performance. But that’s just step one. Its real role is helping re-engineer functions for better growth. In the first of a four-part series, we elaborate how compliance insights are translated into business value by giving visibility to pharmaceutical companies with an international presence. Comparing Spend Across Countries For the Roche Group, whose market covers over 100 countries, the importance of cross-market visibility does not need to be explained. Being able to compare activity across subsidiaries raises […]